Plain-English translation of NCT04920149 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a research study testing whether , a medication already used for bowel inflammation, might help prevent colon cancer in people with Lynch syndrome—a genetic condition that significantly raises the risk of developing colorectal cancer. Half the participants will receive the actual medication for 2 years, while the other half will receive a placebo (a pill with no active ingredient) to see if makes a real difference. The study will involve regular colonoscopies and blood and stool tests to track whether the treatment prevents or slows the growth of abnormal cells.
People with Lynch syndrome have a much higher lifetime risk of colon cancer because of a genetic mutation affecting how their body repairs DNA. Doctors hope that using this medication regularly might reduce that risk, but it hasn't been formally tested for this purpose yet.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the study medication or a placebo once daily for 2 years. During the study, you'll have colonoscopies (typically every 1–2 years) where doctors check your colon and take small tissue samples for research. You'll also provide blood and stool samples at certain visits so researchers can look for early warning signs of cancer development. The study takes place at medical centers in multiple countries, so you should be prepared for regular visits over the 2-year period.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Denmark
Sweden